Inflammation as a new target in CV risk reduction

“Lowering LCL-c is the first, second and third thing we have to do to lower atherosclerotic event rates, but what can we do beyond LDL-c lowering?” asks Prof. Ridker. He talks about targeting inflammation in patients with residual CV risk.

View here